Background: The literature indicates increased rates ofsome medical conditions in patients with anxiety disorders. We used the Saskatchewan Health databases to examine the development ofnonpsychiatric medical diseases in patients with anxiety disorders. This study has a large population base, and the Saskatchewan health plan does not limit the provision ofservices to this populaiton.
P atients with anxiety disorders are frequent users of general medical and specialty services. These disorders are often chronic in nature, and besides causing emotional distress, they affect an individual's occupational and social functioning (1). Because the l-year prevalence for anxiety disorders is estimated at 17.2%, high physical and mental morbidity may have considerable implications for health services costs (2, 3) .
Two community studies on risk factors for cardiovascular disease in selected populations have found that the presence ofanxiety, as measured on different scales, increased the risk for sudden death but not for nonfatal myocardial infarction (4, 5) . Another study, conducted on a cohort ofthe Normative Aging Study, found that a high degree ofworry about general social conditions was associated with a 2-fold increased risk for nonfatal myocardial infarction (6) . A British study, over 10 years of follow-up, found a 3.77 (95% CI 1.64-8.64) Manuscript received August 1999, revised, and accepted March 2000. 'Professor of Psychiatry, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan. 2Professor of Public Health Sciences, University of Alberta, Edmonton, Alberta. 3Psychiatrist, Nanaimo Regional General Hospital, Nanaimo, British Columbia.
relative risk for fatal ischemic heart disease in men with high phobic anxiety (7) . These studies have controlled for several other cardiovascular risk factors such as cigarette smoking, body mass index, blood lipid levels, and blood pressure. Studies that have followed patients with nonfatal myocardial infarction have found that anxiety is a risk factor for the recurrence of cardiac events (8) (9) (10) .
Most studies have used select populations and relatively small numbers of patients. By using Saskatchewan's linked outpatient and hospitalization health databases, we examined the development of nonpsychiatric medical conditions, as well as the occurrence of death, over 10 years in patients who presented with an anxiety disorder. The hypothesis was that patients diagnosed with anxiety disorders would show a higher incidence of chronic medical conditions and mortality compared with a population control group.
Method
The population of Saskatchewan (with the exception of inmates of federal prisons, members of the armed services, the Royal Canadian Mounted Police, and status Indians) is covered by a health plan that reimburses physicians for inpatient and outpatient care. There are no financial limitations or restrictions on care. There are no private medical care institutions in the province. The mid-1989 census reported a population of 1.01 million.
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The diagnostic criteria for anxiety disorders that we followed changed over time and are outlined in Table 1 . Patients with an ICD-9 diagnosis of neurotic depression were specifically excluded to avoid contaminating the cohort with patients who might be diagnosed as suffering from depressive disorders according to the DSM diagnostic system (11).
We drew the control cohort (using 3 control subjects for each anxiety cohort patient) from the same Saskatchewan Health databases, and we matched for sex, age, and location (urban or rural). The matched control subject must have presented to a physician within 5 years of the anxiety subjects' first visit. The exclusion criteria for the control subjects were the same as for the anxiety cohort. In addition, control subjects were excluded ifthey received a psychiatric diagnosis made within 6 months after induction. The medical diagnoses that caused the control subjects to present for treatment were not obtained because we did not consider these relevant.
All men and women over the age of 15 years who had been seen at least twice for an anxiety disorder between January 1980 and March 1990 inclusive were identified from the Saskatchewan Health databases. All physicians were required to provide diagnoses specified by DSM or ICD-9 (Table 1 ). The date of the first diagnosis of an anxiety disorder was used as the induction date. The study's end was December 1991 to allow the outcome events of interest to be observed over at least 18 months of follow-up.
Reasons for exclusion were 1) any treatment for a psychiatric disorder (as defined by DSM-III or -III-R or ICD-9) or any of the study-specified medical conditions (Table 2) in the year prior to study entry; 2) the prescription ofbenzodiazepines, barbiturates, anticonvulsants, lithium, neuroleptics, or miscellaneous anxiolytics in the year prior to induction, regardless of diagnosis; 3) development of any of the specified medical conditions ( "failure event" was defined as the development of any medical condition specified in Table 2 in a subject (anxiety or control group) during follow-up. The "failure time" was the time from first diagnosis (anxiety group) or from induction (control group) to the time of development of a specified medical condition. A "censored case" was defined as a subject who did not develop any of these conditions. From our review of the literature, we selected those medical conditions that we Results frequencies and percentages. Fisher's exact test was used to test the difference in sex ratios between the anxiety and control groups. Two independent sample t-tests examined the differences in mean ages between cases and control subjects. Kaplan-Meier estimates were obtained to describe the disease-free distribution in the anxiety and control groups. The difference in the disease-free distribution was tested using the Mantel-Cox statistic. Cox's proportional hazards models were used to examine the differences in disease-free distribution between anxiety and control groups after adjusting for age and sex. Hazard ratios and 95% CIs were used to describe the risk of a particular condition occurring in patients with anxiety compared with control subjects.
The hazard ratios, 95% CIs, test statistics, and P values for the significant medical outcomes are given in Table  4 . Twenty-three members of the anxiety cohort (2.7%) and 21 of the control subjects (1.2%) developed cerebrovascular disease. After the statistics were adjusted for age and sex, patients with anxiety were twice as likely as control subjects to develop cerebrovascular disease (95% CI 1.09-3.64). The adjusted hazard ratio for cerebrovascular disease was the highest of all the medical outcomes. The hazard ratio for developing one of the atherosclerotic conditions was 1.99 (95% CI 0.93-4.13). The number of patients who developed neoplastic disorders and miscellaneous cardiac conditions (such as
We identified 866 patients with anxiety and matched them with 1791 control patients. There were more women than men in both the control group (58.2%) and in the anxiety cohort (59.9%), but the sex ratios were not different (Fisher's exact test, P = 0.42). The mean ages ofthe anxiety and control cohorts were 36.5 years (SD 12.2) and 34.4 years (SD 14.0) respectively. The age difference was statistically significant (t-test for independent samples, P < 0.001, df2655, 95% CI 1.05-3.13), but an age difference of2.1 years is probably not important. Neither age nor sex was a significant predictor of the specified medical conditions following the onset of an anxiety disorder. There was no significant difference between the anxiety and control groups in the number of deaths (14 and 28 deaths respectively). The number of subjects in each cohort and the medical outcomes are given in Table 3 .
There was a significant difference in the disease-free distribution between the anxiety and the control groups (Mantel-Cox statistic 38.536, df 1, P < 0.001). The cumulative survival rates for anxiety and control subjects who were free of medical events for 5 years were about 55% and 70% respectively.
The calculated hazard ratio, or relative risk, for patients with anxiety was 1.4 (95% CI 1. 25 considered relevant. For censored cases, the termination date was specified as death, end of health coverage by the province, or the end of the study period, whichever occurred first. The specific causes of death were not available for analysis, and we could not distinguish between natural and unnatural causes of death.
Means and standard variations were used to describe continuous variables. Discrete variables were described with VOl 'J:l, 1"'l0:l cardiomyopathies) was insufficient for meaningful statistical analysis.
Discussion
We examined the risk of developing several medical disorders prospectively in a group ofpatients diagnosed with anxiety disorders. The most striking finding is the increased risk for cerebrovascular and cardiovascular diseases and related conditions such as atherosclerosis and ischemic heart disease. The fmding of Weissman and colleagues, who used the New Haven data from the Epidemiologic Catchment Area study, supports this. They found that patients with panic disorder were at higher risk for developing stroke compared with groups with other psychiatric disorders (including obsessive-compulsive disorder) and with no psychiatric disorder (12) .
Our data indicate that patients with anxiety disorders develop gastrointestinal disorders at 1.4 times the rate of that for control subjects. Gastrointestinal disorders were defined as duodenal ulcer, peptic ulcer, gastritis, and duodenitis. We excluded irritable bowel syndrome (IBS) because gastrointestinal symptoms resembling IBS commonly occur in patients with panic disorder (13) . The increased risk of substance abuse could increase gastrointestinal symptoms.
There was a small but significant increase in the risk ofdeveloping respiratory conditions (hazard ratio 1.28). Patients with panic disorder had a higher incidence ofrespiratory disorders compared with subjects with relational problems in a correlational study (14) . Allgulander found higher than expected mortality from obstructive pulmonary disease (standardized mortality ratio [SMR] 2.8) in male patients who had a discharge diagnosis of anxiety neurosis (15) . The SMR is the number of deaths occurring among the probands divided by the number of deaths expected if the age-specific death rate were the same as in the general population. Whether the association occurs through the effects of smoking or some other mechanism is not known (14) (15) (16) .
The salient finding is the link between patients who have been identified with anxiety and the later occurrence ofcardiac and cerebrovascular disease. The increased risk for cardiovascular disease in patients with depression is well documented (16) (17) (18) . One review of the literature to 1984 concluded that the effect size for anxiety as a cause for heart disease was not as robust as for depression and appeared stronger for studies conducted prior to 1977 (18) . More recent studies have used various questionnaires for defming anxiety and have found that anxiety is a predictor of coronary heart disease (19) . These studies have controlled for social class, age, alcohol use, cigarette smoking, family history, and physical risk factors (4,5,7). Vaillant found that men who had higher ratings on a mood disorders continuum while in their 20s were less likely to be in good physical or emotional health and more likely to be dead or disabled at age 70 years (20) . The relevant psychiatric factor is possibly a group of negative emotions, including anxiety, depression, and anger (9, (18) (19) (20) (21) .
Possible explanations for the association between anxiety and cardiac and cerebrovascular diseases include unhealthy lifestyles and reduced compliance with medical treatments (19) . Stein and others found increases in noradrenergic activity in response to orthostatic challenge in social phobia (22) . There is strong evidence for increased noradrenergic and corticotropin-releasing factor activity in anxiety and depressive states (23) . Sudden frightening events, which are more common in anxiety, are associated with arrhythmias and increased platelet aggregation (17) . Consistent changes in peripheral noradrenergic activity in the resting state in panic have not been found, but there is evidence for decreased vagal tone with orthostatic challenge (22) . Stress is associated with myocardial ischemia and endothelial abnormalities (19) . Heart rate variability does decrease in panic disorder, and this is associated with a higher sympathetic-parasympathetic activity ratio, a risk factor for cardiac events (24, 25) . Anxiety, and possibly depression, increases the risk for hypertension, which could be a mediating variable for the development of cardiac and cerebrovascular disease (26, 27) . Rozanski and others discuss the possibility that combined risk factors may act synergistically to increase the risk for coronary events (19) .
This study has several limitations. There is high comorbidity between anxiety and depression, so studies ofanxiety as a risk factor likely included patients who had depression or for whom depression was the more proximal mood state before the medical outcome (28) . We did not study the suppression ofnegative emotion, which has been found to be a risk factor for death in patients with coronary heart disease (29) . The psychiatric and medical diagnostic groups that we studied are relatively broad, and physicians assigned the diagnoses mainly for billing purposes. We selected only patients who had been diagnosed with anxiety on at least 2 occasions, but this is only a portion of patients who present to physicians with underlying anxiety problems (30) . Symptoms of several of the outcome medical conditions occur in anxiety, and patients who were experiencing the early stages of these medical syndromes may have been misdiagnosed as having anxiety. We tried to eliminate this source of error by excluding patients who had any ofthe medical conditions in the year before induction and 6 months after the anxiety diagnosis (31) . Patients with anxiety also are more likely to visit physicians and thus to receive medical diagnoses (1). Another limitation ofthis study is that we did not consider smoking, which is typically more common among patients with psychiatric conditions (19) . Other studies with similar findings have collected data on smoking and controlled for this in their calculations (4-7). This study provides additional evidence for an association between anxiety disorders and later medical morbidity, thereby supporting the need for further epidemiological studies to defme this association more accurately as well as the need for clinical studies to explore the possible pathophysiological mechanisms. If anxiety and mood disorders are predictors of medical morbidity, and because these negative mood states often first appear in teenagers and young adults, early diagnosis and intervention could have a preventative effect against medical morbidity (19, 21) . 
